Hualan Biological Engineering Inc.
002007
Rank in Stocks
#4386
Hualan Biological Engineering Inc. operates as a biopharmaceutical company,... Hualan Biological Engineering Inc. operates as a biopharmaceutical company, specializing in the research, development, production, and commercialization of a diverse portfolio of medical products within the People's Republic of China. Its offerings span plasma-derived therapies, various viral and bacterial vaccines, recombinant proteins, and other advanced biologics. The company's extensive range of plasma products includes essential components like human albumin, a broad spectrum of human immunoglobulins (such as intravenous, rabies, hepatitis B, and tetanus formulations), and vital coagulation factors like human prothrombin complex and factor VIII. Hualan also provides specialized solutions such as lyophilized human thrombin for external use and surgical fibrin glue. In its vaccine division, Hualan offers critical immunizations, including several influenza vaccines (e.g., split virus, A H1N1, and quadrivalent forms), recombinant hepatitis B vaccine, and ACYW135 meningococcal polysaccharide vaccine. The company actively pursues strategic collaborations with key scientific organizations, most notably the Chinese Academy of Sciences, as well as other esteemed research institutes and enterprises. Established in 1992, Hualan Biological Engineering Inc. is headquartered in Xinxiang, People's Republic of China.
Share Price
$1.92
Market Cap
$3.50B
Change (1 day)
-1.39%
Change (1 year)
-19.45%
Country
CN
Trade Hualan Biological Engineering Inc. (002007)
Category
Healthcare
Revenue for Hualan Biological Engineering Inc. (002007)
Revenue in Oct 2026 TTM: 0
According to Hualan Biological Engineering Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Hualan Biological Engineering Inc. from 2001 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2025 | $654.03M | 9.01% |
| 2024 | $599.96M | -20.50% |
| 2023 | $754.65M | 15.24% |
| 2022 | $654.83M | -6.18% |
| 2021 | $697.97M | -9.23% |
| 2020 | $768.93M | 44.71% |
| 2019 | $531.35M | 13.62% |
| 2018 | $467.67M | 28.48% |
| 2017 | $363.99M | 30.62% |
| 2016 | $278.65M | 22.95% |
| 2015 | $226.64M | 12.89% |
| 2014 | $200.76M | 8.96% |
| 2013 | $184.25M | 18.15% |
| 2012 | $155.95M | 2.26% |
| 2011 | $152.50M | -20.21% |
| 2010 | $191.14M | 6.92% |
| 2009 | $178.77M | 156.72% |
| 2008 | $69.64M | 44.80% |
| 2007 | $48.09M | 6.35% |
| 2006 | $45.22M | 1.03% |
| 2005 | $44.76M | 15.46% |
| 2004 | $38.76M | 26.84% |
| 2003 | $30.56M | 46.50% |
| 2002 | $20.86M | 38.80% |
| 2001 | $15.03M | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $12.62B | - |
US
|
|
| $2.23B | - |
US
|
|
| $15.74B | - |
AU
|
|
| $6.02B | - |
NL
|
|
| - | - |
CH
|
